A5051572125- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Metabolism, Diabetes, and Cancer
- PI3K/AKT/mTOR signaling in cancer
- Neuroendocrine Tumor Research Advances
- Chronic Lymphocytic Leukemia Research
- Brain Metastases and Treatment
- Cancer Immunotherapy and Biomarkers
- Cancer-related Molecular Pathways
- Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Cancer Cells and Metastasis
- Lung Cancer Treatments and Mutations
- Single-cell and spatial transcriptomics
- Prostate Cancer Treatment and Research
- Cancer Risks and Factors
- PARP inhibition in cancer therapy
- Colorectal Cancer Treatments and Studies
- Radiopharmaceutical Chemistry and Applications
- Medical Imaging Techniques and Applications
- Endometriosis Research and Treatment
- BRCA gene mutations in cancer
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
2019-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2019-2025
Policlinico Umberto I
2015-2016
Sapienza University of Rome
2015
Abstract Background The optimal treatment approach for hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2-negative MBC) with aggressive characteristics remains controversial, lack of randomized trials comparing cyclin-dependent kinase (CDK)4/6-inhibitors (CDK4/6i) + endocrine therapy (ET) chemotherapy ET. Materials and methods We conducted an open-label phase II trial (NCT03227328) to investigate whether ET is superior CDK4/6i HR+/HER2-negative MBC features. PAM50...
Proton-pump-inhibitors (PPIs) are frequently prescribed for the management of anticancer drug-related gastrointestinal symptoms. Palbociclib is a weak base with pH-dependent solubility and potential drug-drug interaction at absorption level may affect clinical pharmacokinetics. The current study was aimed investigating effect co-administration PPIs palbociclib on progression-free survival (PFS) in metastatic breast cancer (mBC) patients.Patients affected by estrogen receptor-positive, human...
In spite of the effectiveness endocrine therapy plus cyclin-dependent kinase (CDK) 4/6 inhibitors as first-line treatment for estrogen receptor (ER)-positive, erb-b2 tyrosine 2 (ERBB2 [formerly HER2/neu])-negative (ER+/ERBB2-) metastatic breast cancer (MBC), patients eventually develop resistance, and most will receive chemotherapy. The METEORA-II trial compared a metronomic all-oral with intravenous (IV)
Background: Cyclin-dependent kinase 4 and 6 (CDK4 CDK6) inhibitors have changed the therapeutic management of hormone receptor-positive (HR+) metastatic breast cancer (mBC) by targeting cell cycle machinery overcoming endocrine resistance. However, a large number patients present disease progression due to cells resisting CDK4/6 inhibitors. Our research considers which clinicopathological characteristics could be useful in identifying who might respond analyzing retrospective case series...
Abstract Background Trastuzumab deruxtecan (T-DXd) demonstrated unprecedented efficacy in patients with pretreated HER2+ metastatic breast cancer (mBC). However, few data are available about its routine clinical practice. In this multicenter retrospective study, we examined effectiveness and safety of T-DXd a real-world population. Methods Clinico-pathological information mBC who received were collected from 12 Italian hospitals. HER2 status was determined locally. Patients at least one...
Tumor dissemination to the central nervous system (CNS) is almost a rule in treatment journey of advanced HER2+ breast cancer (BC). Recent results demonstrated high intracranial efficacy with Trastuzumab Deruxtecan (T-DXd). However, real-world evidence lacking literature. We conducted multicenter, observational, retrospective analysis on 39 cases collected at 12 Italian Oncological Units. Patients brain metastases (BMs) from HER2 + BC treated T-DXd various lines were enrolled. Primary...
CDK4/6 inhibitors (CDK4/6i) are recommended in patients with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer (ABC). Up to now, no prognostic biomarkers have been identified this setting. We retrospectively analyzed the expression of progesterone (PR) and Ki67, assessed by immunohistochemistry, 71 ABC treated CDK4/6i impact these markers on progression-free survival (PFS). The majority 63/71 (88.7%) received palbociclib, 4 (5.6%) ribociclib, abemaciclib. A higher median...
Abstract Abemaciclib demonstrated clinical benefit in women affected by HR+/HER2− advanced breast cancer (aBC). Drug-drug interactions (DDIs) can lead to reduced treatment efficacy or increased toxicity. This retro-prospective study aimed evaluate outcomes, DDIs’ impact, and toxicities of abemaciclib combined with endocrine therapy a real-world setting. Patients from 12 referral Italian hospitals aBC who received were included. Clinical data about comorbidities, concurrent medications,...
: Patients with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (mBC) generally receive hormonal therapy (HT) combined CDK4/6 inhibitors (CDK4/6i). Despite this treatment, resistance mechanisms to CDK4/6i emerge and the majority of these patients experience disease progression (PD). This highlight necessity uncover mechanism through identification specific biomarkers. The primary objective is assess accuracy feasibility a novel multi-gene target panel NGS assay on circulating...
Bevacizumab in combination with taxanes HER2-negative metastatic breast cancer (MBC) patients has shown improved progression-free survival (PFS), despite the lack of clear overall (OS) benefit. We performed a retrospective analysis to evaluate impact paclitaxel-bevacizumab and maintenance therapy bevacizumab (BM) endocrine (ET) real-world practice. identified 314 MBC treated 12 centers. Overall, median PFS OS were 14 40 months, respectively. Among 254 potentially eligible for BM, 183...
Circulating tumor cells' (CTCs) heterogeneity contributes to counteract their introduction in clinical practice. Through single-cell sequencing we aim at exploring CTC metastatic breast cancer (MBC) patients. Single CTCs were isolated using DEPArray NxT. After whole genome amplification, libraries prepared for copy number aberration (CNA) and single nucleotide variant (SNV) analysis sequenced Ion GeneStudio S5 Illumina MiSeq, respectively. demonstrate distinctive mutational signatures but...